Individualizing Optimal Dosing of Anti-Thymocyte Globulin in Allogeneic Hematopoietic Cell Transplantation

Chronic graft vs. host disease (cGVHD) remains one of the major causes of treatment failure following allogeneic hematopoietic cell transplantation (HCT) as it results in considerable morbidity and mortality (1). The burden of cGVHD continues to increase with widespread use of peripheral grafts and unrelated donors demanding new approaches to curtail this challenge in future transplants (2). Allo-reactive lymphocytes within the graft are major players thus attempts at T-cell depletion have been a great area of interest.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Biology | Transplants